News
-
Latest data show peripheral vasopressors safer, quicker than central ports
Results from a recent analysis of the CLOVERS trial demonstrated a similar 90-day mortality rate with fewer complications for vasopressors compared with central venous catheter administration for the management of sepsis-induced hypotension.
-
Viloxazine-trazodone combo shows promise for OSA relief
Investigator Ludovico Messineo, MD, PhD, said lower dosages will need to be tested to ensure that the beneficial effects on OSA severity are maintained while minimizing side effects.
-
Azelastine nasal spray shows promise in preventing SARS-CoV-2 infections
Researcher Robert Bals, MD, PhD, said this is a starting point, a signal of efficacy that warrants confirmation in larger, multicentric, phase 3 trials.
-
No benefit found for conservative oxygen therapy for adults who are critically ill
While the approach did not outperform usual therapy, it was not inferior to standard treatment either, suggesting additional studies of SpO2 goals are warranted.
-
Asthma self-management app beats usual care for asthma control
Researcher Jordan Silberman, MD, PhD, said the findings—which varied by race—underscore the need for culturally adaptive strategies to ensure equitable engagement across all populations.
-
Study identifies key environmental exposures associated with risk of interstitial lung disease
Bradford C. Bemiss, MD, MSc, said the findings underscore the importance of asking patients about potential workplace inhalation exposures.
-
Study shows nurse-led family support reduces adverse outcomes, improves ICU satisfaction
Timothy Kinsey, DMSc, PA-C, FCCP, said recent findings offer a strategy for mitigating long-term harm for families of patients who are critically ill.
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Moderate to severe OSA increases risk of severe COVID-19
According to critical care specialist Lina Miyakawa, MD, FCCP, the findings are a reminder that OSA “is not just a sleep disorder but a systemic condition with meaningful public health implications.”
